🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder

    phase 3 small molecule terminated

    1 trial

  2. SPN-810 (18 mg)

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  3. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  4. STELARA 90 mg solution for injection in pre-filled syringe, Solution for injection in pre-filled syringe without Ustekinumab 45, Solution for injection in pre-filled syringe without Ustekinumab 90, STELARA 45 mg solution for injection, JNJ-77242113-AAC Placebo tablet, JNJ-77242113

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  5. SUZ

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 3 small molecule completed

    1 trial

  6. SV-BR-1-GM

    BriaCell Therapeutics

    Breast Cancer

    phase 3 mab active

    2 trials

  7. SYLVANT 400 mg powder for concentrate for solution for infusion, ABIRATERONE ACETATE, AMG 509, ABIRATERONE ACETATE, ENZALUTAMIDE, AMG 509, AMG 509, CABAZITAXEL

    Amgen

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  8. Safinamide 100 mg PLACEBO: Safinamide 100 mg PLACEBO film-coated tablets have the same composition as the relevant Investigational Medicinal Products except for the presence of Active Substance that is missing in the placebo formulations. The missing amount of active substance Safinamide methanesulfonate is replaced in the PLACEBO formulation with the same amount of Microcrystalline cellulose, one of the excipients already present in the authorised formulation, Xadago 100 mg film-coated tablets, Xadago 50 m

    Verona Pharma Ireland Limited

    PARKINSON’S DISEASE WITH MOTOR FLUCTUATIONS

    phase 3 small molecule active

    1 trial

  9. Saline, 0.9% sodium chloride solution IV infusion marketed authorized will be used as the placebo and will be supplied by the site. the SmPC previously authorized are Country specific. for Belgium, Spain and Sweden per local requirements under CTDs no SmPCs were submitted., Delandistrogene moxeparvovec-rokl

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  10. Saphnelo 300 mg concentrate for solution for infusion, Anifrolumab Placebo

    AstraZeneca AB

    Active Proliferative Lupus Nephritis

    phase 3 small molecule active

    1 trial

  11. Sapropterin Dihydrochloride

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonurias

    phase 3 small molecule completed

    3 trials

  12. Sapropterin dihydrochloride

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria

    phase 3 small molecule completed

    4 trials

  13. Sar444671 placebo - matched placebo for test, Rilzabrutinib

    Sanofi-aventis Healthcare Pty Ltd

    Blood and lymphatic diseases

    phase 3 small molecule active

    1 trial

  14. Sar444671 placebo - matched placebo for test, Rilzabrutinib

    Sanofi-aventis Healthcare Pty Ltd

    Autoimmune haemolytic anaemia

    phase 3 small molecule active

    1 trial

  15. Sativex

    Jazz Pharmaceuticals Ireland Limited

    Pain

    phase 3 small molecule completed

    6 trials

  16. Sativex

    Jazz Pharmaceuticals Ireland Limited

    Cerebral Palsy

    phase 3 small molecule completed

    1 trial

  17. Sativex®

    Jazz Pharmaceuticals Ireland Limited

    Detrusor Overactivity

    phase 3 small molecule completed

    1 trial

  18. Sativex®

    Jazz Pharmaceuticals Ireland Limited

    Spasticity

    phase 3 small molecule completed

    3 trials

  19. Secukinumab

    Novartis Pharmaceuticals

    Psoriatic Arthritis

    phase 3 small molecule completed

    2 trials

  20. Secukinumab

    Novartis Pharmaceuticals

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  21. Secukinumab

    Novartis Pharmaceuticals

    Ankylosing Spondylitis

    phase 3 small molecule completed

    1 trial

  22. Secukinumab (75 mg)

    Novartis Pharmaceuticals

    Psoriatic Arthritis

    phase 3 small molecule completed

    1 trial

  23. Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.

    Novartis Pharmaceuticals

    Ankylosing Spondylitis

    phase 3 small molecule completed

    1 trial

  24. Selatogrel

    Viatris Pharmaceuticals Co.,

    Acute Myocardial Infarction

    phase 3 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources